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Available online 22 October 2015The importance of biomarkers in prostate cancer medicine is
increasing as they are now commonly used as companion di-
agnostics for prediction and prognostication of response and sur-
vival parameters. In terms of screening, they can be important for
early diagnosis and prognosis for late diagnosis, and used for
monitoring. They can be derived from tissue sources such as the
primary tumour, metastatic sites such as bone and lymph nodes or
as circulating markers found in blood or urine. Most importantly,
biomarkers now can comprise DNA, epigenetic modiﬁcations of
DNA, RNA species, proteins (most commonly), and even a new
generation of bio-molecular molecules such as exosomes is
emerging. In castrate resistant prostate cancer clinical trials, they
can be used to direct precision medicine.
As discussed in my other abstract, there is a range of emerging
molecular aberrations deﬁning castrate resistant prostate cancer in
terms of prognosis and molecular subtypes enabling matching
molecular aberrations to systemic therapies. These biomarkers may
be limited by access such as availability and affordability at present
but will soon arrive in the clinic. They may direct clinical trial de-
signswhether they be biomarker driven, such as “basket” or “Nof 1”
studies. However, there are signiﬁcant regulatory hurdles and cost
effective studies that need to accompany these areas before
becoming routine in the clinic. Recent post-hoc analyses of clinical
trials using novel androgen synthetic inhibitors such as abiraterone
acetate in castrate resistant prostate cancer have demonstrated that
radiographic progression free survival may be stratiﬁed as a func-
tional percentage in PSA decline.1 Indeed, the longest radiographic
progression free survival is associatedwith a greater than 90% fallen
PSA compared to patients with no decline.2 Biomarkers such as this
may be added to prognostic multi-variant models using clinical
parameters such as LDH, performance status, presence or absence of
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p2287-8882 e2287-903Xlevels of serum alkaline phosphatase or prior to the commencement
of androgen deprivation therapy to initiation of abiraterone acetate
use.3 Validation of models such as these across different patient
groups from different institutions has enabled reasonable
consensus in this approach.4 Indeed the latest iteration of ap-
proaches such as this may be incorporated in internet-enable no-
mograms which may be used in the clinic in discussion with
patients for decision making (https://www.cancer.duke.edu/
Nomogram/ﬁrstlinechemotherapy.html). Other clinical biomarkers
such as PSAdoubling timemayalso be used to assess prognosis after
chemotherapy such as docetaxel use for castrate resistant prostate
cancer.5 Using clinical data such as this novel biomarkers may be
incorporated such as circulating tumour cells using CLIA/FDA
certiﬁed immunomagnetic selection technology.6 Circulating
tumour cell counts of less than 5 cells per 7.5mL are associatedwith
a signiﬁcantly increased probability of survival compared to 5 or
more circulating tumour cells perml.7 Indeed combining circulating
tumour cell concentration with normal or elevated levels of lactate
dehydrogenase is extremely powerful in predicting overall survival.
Newer molecular analyses of castrate resistant prostate cancer
are clearly identifying multiple common genetic aberrations such
as androgen receptor ampliﬁcation. This ampliﬁcation may be seen
as one mechanistic function of resistance in response to previous
therapy (acquired resistance) and signiﬁcant trends have been re-
ported in early clinical studies.8,9 Recent long-range epigenetic re-
modelling data from Australia 10 has demonstrated activation of
aberrant domains such as kallikrein3 (PSA). Other epigenetic
changes such as the expression of microRNA, MiR-20a, MiR-21, and
MiR-141 may distinguish molecular sub-types as well as stratify
according to metastatic potential.11
Tremendous excitement has emerged over the last eighteen
months with the identiﬁcation of ligand binding domain splice
variants of the androgen receptor, most important of which is the
AR-V7 variant which due to its loss of the ligand binding is associ-
ated with intrinsic resistance to androgen receptor targeting thera-
pies. Antonorakis et al have clearly demonstrated an association
between the presence of AR-V7 containing circulating tumour cells
and overall survival both for abiraterone and enzalutamide.6 In an
update of this analysis, for patients receiving docetaxel, however,
there was no association between the presence or absence of this
splice variant and response to treatment.12 In their ﬁnal provocative
analysis there is a suggestion that if a patient has signiﬁcant amounts
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likely to be associated with improvement in PSA progression free
survival as well as progression free survival but not overall survival.
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